App-Quantinova.ai

Predictors of Readmission to Hospital Following Acute Stroke

Jiming Fang - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral artery disease

Warfarin

Exposure to Warfarin and the Risks of Stroke and Bleeding Events among Patients with Non-Valvular Atrial Fibrillation: Real-World vs. Clinical Trial

Luke Boulanger - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Non-valvular atrial fibrillation

apixaban

Angiographic Predictors of Stroke after Carotid Artery Stenting - A Qualitative and Quantitative Analysis of 1070 Patients in the Carotid Revascularization Endarterectomy versus Stenting Trial

Jeffrey J Popma - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Carotid artery stenosis

stannous fluoride

Practice-level Variation in use of Recommended Medications among Outpatients with Heart Failure: Insights from the NCDR PINNACLE Program

Paul S Chan - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Angiotensin II

Dapagliflozin in Patients With Type 2 Diabetes and Established Cardiovascular Disease: Hypotension and Volume-related Safety

Lawrence A. Leiter - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Congestive heart failure

Dapagliflozin

Acute Impairment of Microvascular Function Following a High-Fat Meal

Billie-Jean Martin - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Epigenetic Basis for the Heterogeneity of VCAM1 Expression in Cytokine Activated Vascular Endothelium

Gary C Chan - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

N/A

Nod1/RIP2 Signaling Regulates Cardiac Hypertrophic Response After Pressure Overload State

Alan Valaperti - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Phenylephrine

Targeting Endoglin Activity Improves Survival and Reduces Right Ventricular Fibrosis in a Murine Model of Pulmonary Arterial Hypertension

Xiaoying Qiao - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Pulmonary arterial hypertension

TRC105

Arterial Access Site and Outcomes in Patients Undergoing Percutaneous Coronary Intervention With and Without Vorapaxar

Kenneth Mahaffey - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Acute Coronary Syndromes

Vorapaxar

Design, Implementation and Evaluation of a Reduced Cardiac Rehabilitation Program

Sammy Chan - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

N/A

Chronic Iron Deposition following Acute Hemorrhagic Myocardial Infarction: A Cardiovascular Magnetic Resonance Study

Andreas Kumar - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Ischemia-reperfusion injury

N/A

Reprogramming Transgene Offload Releases the Cardiogenic Potential of iPS Cells

Timothy J Nelson - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Leukoencephalopathy, megalencephalic, with subcortical cysts, 2A

N/A

Constitutive Low Levels of P53 Expression Maintain Vascular Endothelial Function in Mice Fed a High Fat Diet

Eric Thorin - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

Superoxide dismutase

Prevalence of Metabolic Syndrome in Healthy Middle-Aged Adults: Insights from the Primary Care Audit of Global Risk Management (PARADIGM) Study

Michelle Tsigoulis - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Metabolic syndrome

N/A

Arrhythmia Risk Profiles in Patients with Coronary Artery Disease: The Influence of Diabetes

Olli-Pekka Piira - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Coronary Artery Disease

N/A

Prevalence of Impaired Fasting Glucose in Healthy Middle-Aged Adults: Insights from the Primary Care Audit of Global Risk Management (PARADIGM) Study

Mahesh Kajil - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

N/A

Benefits of Dabigatran versus Warfarin in Hypertensive Patients With Atrial Fibrillation: Results From The Re-ly Trial

Stuart Connolly - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Arrhythmia

Pradax

The Newly Designed Dual Guanylyl Cyclase A and B Activator, CU-NP, Elicits Favorable Cardiorenal Hemodynamic Actions without Hypotension and Activates the Second Messenger cGMP in Isolated Cardiac Fibroblasts and Glomeruli

Candace Y W Lee - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Angiotensin II

miR-145 Is a Key Regulator of Cardiac Myofibroblast Differentiation

Shu-hong Li - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

N/A

Filters

28841 Abstracts